Fabrication of gelatin/silk fibroin/phage nanofiber scaffold effective against multidrug resistant
Find in your Library
Drug development and industrial pharmacy
OBJECTIVE: The alarming rise of multi-drug resistant (MDR) has prompted the World Health Organization to consider it a serious threat to human health. Although phage (Phg), an effective antibacterial treatment option, can maintain long-term infectivity lyophilized storage, freeze-drying can be expensive and time-consuming. Thus, we propose electrospun gelatin/fibroin (G/F) nanofibrous formulation for dehydrating and storing phage against MDR . SIGNIFICANCE: The formulation of phage within the nanofibrous structure of the electrospun G/F scaffold would result in antimicrobial activity against MDR leading to enhanced wound healing. METHODS: Phg effective against MDR was isolated, characterized and loaded within G/F nanofibers by electrospinning. Morphology, crystallinity and thermal stability as well as the antimicrobial activity and the biocompatibility of the developed G/F/Phg nanofibers were determined. RESULTS: Phg-loaded G/F nanofibers revealed an amorphous structure with good thermal stability at temperatures below 300 °C and exhibited effective antibacterial activity against MDR with ∼2 log reduction in the bacterial count which increased to ∼4 log reduction in bacterial count after 16 h as compared to both the G/F nanofibers and the negative control. Lack of cytotoxic effects on cultured fibroblasts supported the biocompatibility of G/F/Phg nanofibers. CONCLUSION: The developed G/F/Phg nanofibers are able to maintain the viability of phage and represent a promising antimicrobial dressing for wounds infected with MDR .
Sarhan, W. A.
Salem, H. G.
Khalil, M. A.
El-Sherbiny, I. M.
(2021). Fabrication of gelatin/silk fibroin/phage nanofiber scaffold effective against multidrug resistant. Drug development and industrial pharmacy, 47(6), 947–953.
Sarhan, W, et al.
"Fabrication of gelatin/silk fibroin/phage nanofiber scaffold effective against multidrug resistant." Drug development and industrial pharmacy, vol. 47,no. 6, 2021, pp. 947–953.